Does your Pharma Marketing Campaign use the Most Effective Channels?

| October 4, 2016

article image
After decades in pharma marketing and measurement, I’ve heard my fair share of conventional wisdoms, many of which directly impact marketing decisions. One of the most common thoughts that comes to mind is this: If your brand has a limited budget for multichannel marketing (MCM), journal ads and digital banner ads are a good place to start.

Spotlight

DAVA Oncology

Optimize the recruitment and retention of patients in cancer clinical trials through the use of physician-focused approaches. DAVA has a proven track record having completed more than 45 Phase I to III trials and over the past six years with an average accrual enhancement rate of 30-40%.

OTHER ARTICLES

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 4, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 4, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | March 4, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

Pricing of drugs – at what cost?

Article | March 4, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Spotlight

DAVA Oncology

Optimize the recruitment and retention of patients in cancer clinical trials through the use of physician-focused approaches. DAVA has a proven track record having completed more than 45 Phase I to III trials and over the past six years with an average accrual enhancement rate of 30-40%.

Events